Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today reported results from its randomized, open-label, multicenter Phase 2 clinical trial...
View ArticleResearchers to Present New Data on Asfotase Alfa in Children with...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new functional and quality-of-life data from...
View ArticleClik here to view.
Alexion to Present at the 2015 Leerink Global Healthcare Conference
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the 2015 Leerink Global Healthcare...
View ArticleNew Data from a Natural History Study in Patients with Infantile- and...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new data from a retrospective, multinational...
View ArticleAlexion to Present at Investor Conferences
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences: Cowen and...
View ArticleAlexion Joins Patient Organizations Worldwide in Support of International...
Dateline City: CHESHIRE, Conn. Company will participate in events across the globe to raise awareness of the need for improved diagnosis and treatment for patients with rare diseases CHESHIRE,...
View ArticleFDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
View ArticleAlexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday,...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the Company will report its financial results for the first quarter...
View ArticleAlexion Announces Presentations at 2015 American Transplant Congress,...
Dateline City: CHESHIRE, Conn. --Presentations to Include Eculizumab Study in AMR, Burden of Disease AMR Study and Study Evaluating the Role of Complement in DGF -- --Study Underscoring the Benefit of...
View ArticleAlexion Reports First Quarter 2015 Results
Dateline City: CHESHIRE, Conn. – Soliris Net Product Sales Increased to $600.3 Million; 25 Percent Growth Compared to Year-ago In-quarter Sales, Despite Increased Currency Headwinds – – Steady Soliris...
View ArticleAlexion to Present at Investor Conferences
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at three upcoming investor conferences:...
View ArticleResearchers Present New Data from Phase 2 Clinical Trial of Eculizumab...
Dateline City: CHESHIRE, Conn. – Preliminary Data Presented at 2015 American Transplant Congress (ATC) – – Additional Studies Presented at ATC Illustrate Burden of Disease in AMR and Explore Role of...
View ArticleAlexion to Acquire Synageva to Strengthen Global Leadership in Developing and...
Dateline City: CHESHIRE, Conn. & LEXINGTON, Mass. -- Expands Alexion’s metabolic franchise with the addition of Kanuma™ (sebelipase alfa) for LAL Deficiency (LAL-D) -- -- Launches of Kanuma and...
View ArticleAlexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting...
Dateline City: CHESHIRE, Conn. & LEXINGTON, Mass. CHESHIRE, Conn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA)...
View ArticleAlexion to Present at Investor Conferences
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences: William...
View ArticleAlexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that it has accepted for exchange all 21,021,124 shares validly tendered...
View ArticleAlexion Completes Acquisition of Synageva
Dateline City: CHESHIRE, Conn. — Strengthens global leadership in serving patients with devastating and rare diseases — — Expands premier global metabolic rare disease franchise with the addition of...
View ArticleAlexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and...
Dateline City: CHESHIRE, Conn. - CHMP Recommends Marketing Authorization for Strensiq for Patients with Pediatric-Onset HPP - - CHMP Recommends Marketing Authorization for Kanuma for Patients of all...
View ArticleStrensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment...
Dateline City: CHESHIRE, Conn. – First Approved Treatment for Japanese Patients Suffering from HPP, a Life-Threatening Ultra-Rare Metabolic Disorder – CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion...
View ArticleAlexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday,...
Dateline City: CHESHIRE, Conn. CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the Company will report its financial results for the second quarter...
View Article
